ML
ABUS icon

McAdam LLC’s Arbutus Biopharma ABUS Stock Holding History

McAdam LLC’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10
Closed – – 625
2018
Q1 		$0 Buy
+10
New +$53 ﹤0.01% 760

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

McAdam LLC's ABUS Position: Q2 2018 in Review

McAdam LLC sold out of Arbutus Biopharma (ABUS) in Q2 2018, closing a stake of 10 shares.

McAdam LLC first reported a position in ABUS in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 71 funds tracked by Wall St. Rank hold ABUS as of Q2 2018.

  • McAdam LLC reported no remaining Arbutus Biopharma position as of Q2 2018 after selling out during the quarter.
  • McAdam LLC sold 10 Arbutus Biopharma shares in Q2 2018.
  • McAdam LLC first reported a position in Arbutus Biopharma in Q1 2018 and held it in 1 quarter.
  • McAdam LLC's Arbutus Biopharma position peaked at $0 in Q1 2018.
  • 71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2018.

Based on McAdam LLC's 13F filing for Q2 2018, filed 22 Aug 2018.